📊 PLSE Key Takeaways
Is Pulse Biosciences, Inc.. (PLSE) a Good Investment?
Pulse Biosciences exhibits severe fundamental weakness with $19.1M operating losses on only $401K revenue, indicating minimal commercial traction and unsustainable burn rate of $14.6M annually. While the $68.3M cash position and zero debt provide runway to continue operations for approximately 4-5 years, the company has yet to demonstrate a viable business model or path to profitability. Execution risk remains extremely high without evidence of significant revenue acceleration or operating leverage.
Pulse Biosciences, Inc.. Key Strengths (PLSE)
- Strong balance sheet with $68.3M cash and zero long-term debt
- Exceptional liquidity position with 7.26x current ratio providing financial flexibility
- Minimal capital intensity with only $33K capex allows focus on product development and commercialization
PLSE Stock Risks: Pulse Biosciences, Inc.. Investment Risks
- Catastrophic operating losses of $19.1M against $401K revenue indicates fundamental business model failure or extremely early stage with minimal market validation
- Negative operating cash flow of $14.6M annually will deplete cash runway within 4-5 years without achieving cash flow breakeven
- Extreme negative profitability metrics across all measures (-4775.6% operating margin, -4633.7% net margin) demonstrate complete lack of current business viability
Key Metrics to Watch
- Revenue growth rate and trajectory toward meaningful commercial scale from $401K baseline
- Operating cash burn rate trend and timeline to cash flow positive operations
- Gross margins and operating expense ratios once revenue begins scaling materially
- Cash runway depletion timeline and need for additional capital raises
- Path to operating breakeven and positive net income through either revenue growth or cost reduction
Pulse Biosciences, Inc.. (PLSE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.26x current ratio provides a solid financial cushion.
PLSE Profit Margin, ROE & Profitability Analysis
PLSE vs Healthcare Sector: How Pulse Biosciences, Inc.. Compares
How Pulse Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pulse Biosciences, Inc.. Stock Overvalued? PLSE Valuation Analysis 2026
Based on fundamental analysis, Pulse Biosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pulse Biosciences, Inc.. Balance Sheet: PLSE Debt, Cash & Liquidity
PLSE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pulse Biosciences, Inc..'s revenue has declined by 75% over the 5-year period, indicating business contraction. The most recent EPS of $-0.92 indicates the company is currently unprofitable.
PLSE Revenue Growth, EPS Growth & YoY Performance
PLSE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$16.8M | $-0.25 |
| Q3 2025 | N/A | -$12.7M | $-0.21 |
| Q2 2025 | N/A | -$11.4M | $-0.20 |
| Q1 2025 | N/A | -$10.1M | $-0.18 |
| Q3 2024 | N/A | -$10.6M | $-0.19 |
| Q2 2024 | N/A | -$9.9M | $-0.20 |
| Q1 2024 | N/A | -$9.8M | $-0.18 |
| Q3 2023 | N/A | -$10.6M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pulse Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
PLSE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pulse Biosciences, Inc.. (CIK: 0001625101)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLSE
What is the AI rating for PLSE?
Pulse Biosciences, Inc.. (PLSE) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLSE's key strengths?
Claude: Strong balance sheet with $68.3M cash and zero long-term debt. Exceptional liquidity position with 7.26x current ratio providing financial flexibility.
What are the risks of investing in PLSE?
Claude: Catastrophic operating losses of $19.1M against $401K revenue indicates fundamental business model failure or extremely early stage with minimal market validation. Negative operating cash flow of $14.6M annually will deplete cash runway within 4-5 years without achieving cash flow breakeven.
What is PLSE's revenue and growth?
Pulse Biosciences, Inc.. reported revenue of $401.0K.
Does PLSE pay dividends?
Pulse Biosciences, Inc.. does not currently pay dividends.
Where can I find PLSE SEC filings?
Official SEC filings for Pulse Biosciences, Inc.. (CIK: 0001625101) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLSE's EPS?
Pulse Biosciences, Inc.. has a diluted EPS of $-1.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PLSE's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pulse Biosciences, Inc.. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PLSE stock overvalued or undervalued?
Valuation metrics for PLSE: ROE of -28.0% (sector avg: 15%), net margin of -4,633.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PLSE's AI grade for 2026?
Our dual AI analysis gives Pulse Biosciences, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PLSE's free cash flow?
Pulse Biosciences, Inc..'s operating cash flow is $-14.6M, with capital expenditures of $33.0K. FCF margin is -3,647.9%.
How does PLSE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,633.7% (avg: 12%), ROE -28.0% (avg: 15%), current ratio 7.26 (avg: 2).